CN112203660B - 用于治疗银屑病关节炎的方法 - Google Patents

用于治疗银屑病关节炎的方法 Download PDF

Info

Publication number
CN112203660B
CN112203660B CN201980034599.1A CN201980034599A CN112203660B CN 112203660 B CN112203660 B CN 112203660B CN 201980034599 A CN201980034599 A CN 201980034599A CN 112203660 B CN112203660 B CN 112203660B
Authority
CN
China
Prior art keywords
treatment
patient
use according
psoriatic arthritis
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980034599.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN112203660A (zh
Inventor
P·哈里森
L·梅勒内尔斯
C·T·塔塞斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfasigma SpA
Original Assignee
Galapagos NV
Alfasigma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV, Alfasigma SpA filed Critical Galapagos NV
Publication of CN112203660A publication Critical patent/CN112203660A/zh
Application granted granted Critical
Publication of CN112203660B publication Critical patent/CN112203660B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980034599.1A 2018-05-24 2019-05-23 用于治疗银屑病关节炎的方法 Active CN112203660B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1808575.3A GB201808575D0 (en) 2018-05-24 2018-05-24 Methods for the treatment of psoriatic arthrits
GB1808575.3 2018-05-24
PCT/EP2019/063283 WO2019224283A1 (en) 2018-05-24 2019-05-23 Methods for the treatment of psoriatic arthritis

Publications (2)

Publication Number Publication Date
CN112203660A CN112203660A (zh) 2021-01-08
CN112203660B true CN112203660B (zh) 2024-12-31

Family

ID=62812304

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980034599.1A Active CN112203660B (zh) 2018-05-24 2019-05-23 用于治疗银屑病关节炎的方法

Country Status (9)

Country Link
US (2) US12329758B2 (https=)
EP (1) EP3801548A1 (https=)
JP (3) JP2021524472A (https=)
CN (1) CN112203660B (https=)
AU (2) AU2019273664B2 (https=)
CA (1) CA3101386A1 (https=)
GB (1) GB201808575D0 (https=)
MA (1) MA52738A (https=)
WO (1) WO2019224283A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2022013745A1 (en) * 2020-07-13 2022-01-20 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482273A (zh) * 2009-06-26 2012-05-30 加拉帕戈斯股份有限公司 作为jak抑制剂的5-苯基-[1,2,4]三唑并[1,5-a]吡啶-2-甲酰胺化合物
CN104379173A (zh) * 2012-06-22 2015-02-25 加拉帕戈斯股份有限公司 用于治疗炎症的氨基三唑并吡啶及其药物组合物
WO2015117980A1 (en) * 2014-02-07 2015-08-13 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
CN107531694A (zh) * 2015-04-13 2018-01-02 加拉帕戈斯股份有限公司 用于治疗炎性疾病的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156037B1 (en) 1999-01-29 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
JPWO2002087620A1 (ja) 2001-04-27 2004-08-12 中外製薬株式会社 軟骨形成促進剤
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
AU2003275682A1 (en) 2002-10-29 2004-05-25 Shionogi And Co., Ltd. Crystal of inorganic acid salt of cephem compound
EP1601672B1 (en) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
JP2008503712A (ja) 2004-06-21 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ 骨関節炎治療の方法及び手段
US20090209577A1 (en) 2004-08-18 2009-08-20 Pfizer Inc. Novel Triazolopyridine Compounds
EP1799680A2 (en) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridine derivatives as antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
BRPI0716239A2 (pt) 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
CA2693232A1 (en) 2007-07-18 2009-01-22 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009155565A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JPWO2010013768A1 (ja) 2008-07-31 2012-01-12 第一三共株式会社 チアゾリジンジオン化合物の結晶及びその製造方法
JP2013049632A (ja) 2011-08-30 2013-03-14 Kowa Co ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US10376520B2 (en) 2015-04-13 2019-08-13 Galapagos Nv Methods for the treatment of cardiovascular disorders
US20170173034A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
HRP20240112T1 (hr) * 2017-03-14 2024-04-12 Galapagos Nv Farmaceutske tvari koje uključuju inhibitor janus kinaze (jak)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482273A (zh) * 2009-06-26 2012-05-30 加拉帕戈斯股份有限公司 作为jak抑制剂的5-苯基-[1,2,4]三唑并[1,5-a]吡啶-2-甲酰胺化合物
CN104379173A (zh) * 2012-06-22 2015-02-25 加拉帕戈斯股份有限公司 用于治疗炎症的氨基三唑并吡啶及其药物组合物
WO2015117980A1 (en) * 2014-02-07 2015-08-13 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
CN107531694A (zh) * 2015-04-13 2018-01-02 加拉帕戈斯股份有限公司 用于治疗炎性疾病的方法

Also Published As

Publication number Publication date
AU2019273664B2 (en) 2025-01-23
EP3801548A1 (en) 2021-04-14
US20260108530A1 (en) 2026-04-23
CA3101386A1 (en) 2019-11-28
JP2021524472A (ja) 2021-09-13
AU2025202777A1 (en) 2025-05-08
KR20210013168A (ko) 2021-02-03
CN112203660A (zh) 2021-01-08
US12329758B2 (en) 2025-06-17
MA52738A (fr) 2021-04-14
JP7751362B2 (ja) 2025-10-08
JP2025183397A (ja) 2025-12-16
WO2019224283A1 (en) 2019-11-28
GB201808575D0 (en) 2018-07-11
US20210299135A1 (en) 2021-09-30
JP2024069223A (ja) 2024-05-21
AU2019273664A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
US11524964B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20220267342A1 (en) PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US20260108530A1 (en) Methods for the treatment of psoriatic arthritis
US11773106B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20190314382A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
TW202133877A (zh) 全身性紅斑狼瘡中之ｉ型干擾素抑制
TW202126329A (zh) 使用白細胞介素－１７（ｉｌ－１７）拮抗劑治療自體免疫性疾病之方法
EP4356963A2 (en) Treating spondyloarthritic and psoriatic conditions with upadacitinib
CN121969374A (zh) 使用ly3871801治疗自身免疫性和炎症性疾病的剂量方案
KR102955500B1 (ko) 건선성 관절염의 치료 방법
Sadeq et al. Randomized clinical trials on the efficacy and safety of tocilizumab in subjects with Rheumatoid arthritis: a systematic review
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)
US12570664B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20240398790A1 (en) Treating spondyloarthritic conditions with upadacitinib
HK40111335A (en) Treating spondyloarthritic and psoriatic conditions with upadacitinib
Humby et al. O07 Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy
Hawkins 54 Rheumatoid Arthritis and Osteoarthritis
CN120957720A (zh) 三稠环化合物在制备预防和/或治疗炎性疾病药物中的应用
Martín-Varillas et al. AB1017 WHAT IS THE CURRENT SITUATION OF THE PAEDIATRIC RHEUMATOLOGY TRANSITION CARE UNITS?
Walsh et al. O06 Improvements in pain, function and health status with subcutaneous tanezumab compared with placebo in patients with OA: pooled analysis of two randomized controlled trials
TW202511290A (zh) 一種重組抗ＩＬ－２３ｐ１９抗體治療中重度銀屑病的方法
CN118076369A (zh) Cd40l特异性tn3衍生支架及其用于治疗和预防类风湿性关节炎的方法
Dragoi et al. OP0173 Inspiratory Muscle Training as a Method for Improving Aerobic Capacity and Pulmonary Function in Patients with Ankylosing Spondylitis: A Randomized Controlled Study
Moltό et al. THU0357 No specific impact of concomitant fibromyalgia on the anti tnf treatment effect in axial spondyloarthritis patients without radiographic structural damage or objective signs of inflammation
Mohammed Anti-CD-20 Therapy in Refractory Adult Still’s Disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240403

Address after: Bologna, Italy

Applicant after: ALFASIGMA S.P.A.

Country or region after: Italy

Address before: Mechelen

Applicant before: GALAPAGOS N.V.

Country or region before: Belgium

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant